GSK to use BioClinica Interactive Web Response solution

Published: 28-Jan-2011
Regulatory

The pharma giant has signed a multi-year agreement for global trial management technology


GlaxoSmithKline (GSK) has agreed a multi-year enterprise technology deal with US-based BioClinica, enabling it to deploy BioClinica’s Trident IWR (Interactive Web Response) system across its Phase I-IV clinical trials.

Mark Weinstein, ceo of BioClinica, a global provider of integrated, technology-enhanced clinical trial management services located in Newtown, PA, said: ‘GSK had a requirement for a new solution to enable internal staff to configure and manage highly complex IWR clinical studies, and we are pleased GSK chose Trident.’

Trident IWR’s design provides clinical operations personnel with an intuitive way to directly set up, monitor, and maintain randomisation and supplies for their clinical trials, in a fraction of the time previously required.

According to BioClinica, it delivers rapid study setup without the need for programming, while simultaneously delivering world-class IVR (Interactive Voice Response) system phone support through the same simplified configuration process.

BioClinica has also just established a partnership NJ-based CRO, Symbiance.
  • Companies:
  • BioClinica
See more

You may also like

Regulatory

Bioclinica acquires Clinverse

Read more
Expanding into financial management solutions for clinical trials

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  3. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  4. Innovating with purpose for safety and security of outcome Beyond the importance of increasing productivity and generating more output and value with the same input, new ideas and technologies from GEA take innovation a step further
  5. AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Regulatory

Bioclinica acquires Clinverse

Expanding into financial management solutions for clinical trials
Regulatory

BioClinica acquires Synowledge

Adds capabilities in pharmacovigilance and regulatory technology, data analysis and business process management
Regulatory

BioClinica software offers better sponsor control over trial timelines

Programme has potential to change the way sponsors and CROs use technology to run clinical trials
Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Subscribe now